ACADIA Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $231.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $726.4 Mil.
ACADIA Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $1.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.42.
During the past 12 months, the average Revenue per Share Growth Rate of ACADIA Pharmaceuticals was 38.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 17.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 131.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 1109.20% per year. The lowest was -77.60% per year. And the median was -16.20% per year.
ACADIA Pharmaceuticals Revenue Historical Data
The historical data trend for ACADIA Pharmaceuticals's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ACADIA Pharmaceuticals's Revenue
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Revenue falls into.
ACADIA Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $726.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ACADIA Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACAD has been successfully added to your 